The Biomarkers Consortium: practice and pitfalls of open-source precompetitive collaboration.
Precompetitive collaboration is a growing driver for innovation and increased productivity in biomedical science and drug development. The Biomarkers Consortium, a public-private platform for precompetitive collaboration specific to biomarkers, demonstrated that adiponectin has potential utility as a predictor of metabolic responses to peroxisome proliferator-activated receptor (PPAR) agonists in individuals with type 2 diabetes. Despite the challenges overcome by this project, the most important lesson learned is that cross-company precompetitive collaboration is a feasible robust approach to biomarker qualification.
Wagner
J A
JA
Merck, Rahway, New Jersey, USA.
Prince
M
M
Wright
E C
EC
Ennis
M M
MM
Kochan
J
J
Nunez
D J R
DJ
Schneider
B
B
Wang
M-D
MD
Chen
Y
Y
Ghosh
S
S
Musser
B J
BJ
Vassileva
M T
MT
D000818:Animals; D015415:Biomarkers / Q000378:metabolism*; D003299:Cooperative Behavior; D016503:Drug Delivery Systems / Q000379:methods / Q000639:trends; D015195:Drug Design; D004345:Drug Industry / Q000191:economics / Q000379:methods / Q000639:trends; D004465:Economic Competition / Q000191:economics / Q000639:trends; D006801:Humans; D016032:Randomized Controlled Trials as Topic / Q000639:trends
D015415:Biomarkers